News and analysis on diagnostic technologies and applications.
The ulixertinib program is open to adult and adolescent cancer patients who have exhausted other treatment options and who have MAPK pathway alterations.
Sema4 will use its genomics testing abilities and Centrellis health intelligence platform to identify eligible patients for Janssen's oncology clinical trials.
The firm is exploring whether the regimen may work for subgroups of patients with high TMB based on promising signals from the current failed analysis.
The company will seek FDA approval in advanced systemic mastocytosis, a disorder that can turn into cancer in 7 percent of children and 30 percent of adults.
The company, which raised $460 million in an IPO in July, has developed a pipeline of selective agents, two of which have advanced to Phase I clinical trials.
